DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.

Osorio, Ana; Milne, Roger L; Kuchenbaecker, Karoline; Vaclová, Tereza; Pita, Guillermo; Alonso, Rosario; Peterlongo, Paolo; Blanco, Ignacio; de la Hoya, Miguel; Duran, Mercedes; Diez, Orland; Ramón Y Cajal, Teresa; Konstantopoulou, Irene; Martinez-Bouzas, Cristina; Andrés Conejero, Raquel; Soucy, Penny; McGuffog, Lesley; Barrowdale, Daniel; Lee, Andrew; Swe-Brc, Swe-Brc; Arver, Brita; Rantalai, Johanna; Loman, Niklas; Ehrencrona, Hans; Olopade, Olufunmilayo I; Beattie, Mary S; Domchek, Susan M; Nathanson, Katherine; Rebbeck, Timothy R; Arun, Banu K; Karlan, Beth Y; Walsh, Christine; Lester, Jenny; John, Esther M; Whitemore, Alice S; Daly, Mary B; Southey, Melissa; Hopper, John; Terry, Mary B; Buys, Saundra S; Janavicius, Ramunas; Dorfling, Cecilia M; van Rensburg, Elizabeth J; Steele, Linda; Neuhausen, Susan L; Ding, Yuan Chun; Hansen, Thomas V O; Jønson, Lars; Ejlertsen, Bent; Gerdes, Anne-Marie

Published in:
PLoS Genetics

DOI:
10.1371/journal.pgen.1004256

2014

Citation for published version (APA):
Osorio, A., Milne, R. L., Kuchenbaecker, K., Vaclová, T., Pita, G., Alonso, R., ... Benitez, J. (2014). DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS Genetics, 10(4), [e1004256]. https://doi.org/10.1371/journal.pgen.1004256
DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

Netherlands, 104 Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands, 105 Department of Clinical Genetics and GROW, School for Oncology and Developmental Biology, MUMC, Maastricht, The Netherlands, 106 Department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands, 107 Department of Clinical Genetics, Family Cancer Clinic, Erasmus University Medical Center, Rotterdam, The Netherlands, 108 Department of Pathology, Family Cancer Clinic, Erasmus University Medical Center, Rotterdam, The Netherlands, 109 Department of Medical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands, 110 Department of Human Genetics & Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands, 111 The Hereditary Breast and Ovarian Cancer Research Group, Netherlands Cancer Institute, Amsterdam, The Netherlands, 112 Department of Molecular Genetics, National Institute of Oncology, Budapest, Hungary, 113 Molecular Diagnostic Unit, Hereditary Cancer Program, IDIBELL-Catalan Institute of Oncology, Barcelona, Spain, 114 Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland, 115 Postgraduate School of Molecular Medicine, Warsaw Medical University, Warsaw, Poland, 116 Department of Oncology, Landspital University Hospital and BMC, Faculty of Medicine, University of Iceland, Reykjavik, Iceland, 117 Laboratoire de Diagnostic Génétique et Service d’Onco-hématologie, Hopitaux Universitaire de Strasbourg, CHRU Nouvel Hôpital Civil, Strasbourg, France, 118 Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV - IREC5, Padua, Italy, 119 Department of Genetics, Portuguese Oncology Institute, Porto, and Biomedical Sciences Institute (ICBAS), Porto University, Porto, Portugal, 120 Department of Genetics and Computational Biology, Queensland Institute of Medical Research, Brisbane, Australia, 121 Kathleen Cunningham Consortium for Research into Familial Breast Cancer, Peter MacCallum Cancer Centre, Melbourne, Australia, 122 Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United States of America, 123 Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, United States of America, 124 Center for Individualized Medicine, Mayo Clinic, Scottsdale, Arizona, United States of America, 125 Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United States of America, 126 Center for Translational Cancer Research, Department of Biological Sciences, University of Delaware, Newark, Delaware, United States of America, 127 Clinical Genetics Service, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America, 128 Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America, 129 Diagnostic Molecular Genetics Laboratory, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America, 130 Department of Obstetrics and Gynecology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria, 131 Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida, United States of America, 132 Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, United States of America, 133 Clall National Israeli Cancer Control Center, Haifa, Israel, 134 Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada, and Cancer Care Ontario, Departments of Molecular Genetics and Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada, 135 Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada; Laboratory Medicine Program, University Health Network, Toronto, Ontario, Canada, 136 Ontario Cancer Genetics Network: Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada, 137 Division of Human Cancer Genetics, Departments of Internal Medicine and Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, United States of America, 138 Department of Clinical Genetics, Veje Hospital, Veje, Denmark, 139 Section of Molecular Diagnostics, Department of Clinical Biochemistry, Aalborg University Hospital, Aalborg, Denmark, 140 Department of Clinical Genetics, Aarhus University Hospital, Aarhus, Denmark, 141 Department of Clinical Genetics, Odense University Hospital, Odense, Denmark, 142 Sheba Medical Center, Tel Aviv, Israel, 143 Canada Research Chair in Oncogenetics, Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec and Laval University, Québec City, Canada

Abstract

Single Nucleotide Polymorphisms (SNPs) in genes involved in the DNA Base Excision Repair (BER) pathway could be associated with cancer risk in carriers of mutations in the high-penetrance susceptibility genes BRCA1 and BRCA2, given the relation of synthetic lethality that exists between one of the components of the BER pathway, PARP1 (poly ADP ribose polymerase), and both BRCA1 and BRCA2. In the present study, we have performed a comprehensive analysis of 18 genes involved in BER using a tagging SNP approach in a large series of BRCA1 and BRCA2 mutation carriers. 144 SNPs were analyzed in a two stage study involving 23,463 carriers from the CIMBA consortium (the Consortium of Investigators of Modifiers of BRCA1 and BRCA2). Eleven SNPs showed evidence of association with breast and/or ovarian cancer at p<0.05 in the combined analysis. Four of the five genes for which strongest evidence of association was observed were DNA glycosylases. The strongest evidence was for rs1466785 in the NEIL2 (endonuclease VIII-like 2) gene (HR: 1.09, 95% CI (1.03–1.16), p = 2.7×10−3) for association with breast cancer risk in BRCA2 mutation carriers, and rs2304277 in the OGG1 (8-guanine DNA glycosylase) gene, with ovarian cancer risk in BRCA1 mutation carriers (HR: 1.12 95%CI: 1.03–1.21, p = 4.8×10−3). DNA glycosylases involved in the first steps of the BER pathway may be associated with cancer risk in BRCA1/2 mutation carriers and should be more comprehensively studied.


Editor: Marshall S. Horwitz, University of Washington, United States of America

Received 23 October 2013; Accepted 4 February 2014; Published 3 April 2014

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CCO public domain dedication.

Funding: The CNIO study was supported by Mutua Madrileña Foundation (FMMA), Spanish Association against Cancer (AECC08), RTICC 06/0020/1060 and FISPI12/00070. Funding for the iCOGS infrastructure came from: the European Community’s Seventh Framework Programme under grant agreement n 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A10710, C12292/A11174, C5047/A8384, C5047/A15007, C5047/A16092), the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (No. 1 U19 CA 148537 - the GAME-ON initiative), the Department of Defence (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CHHR Team in Familial Risks of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Foundation. SWE-BRCA collaborators are supported by the Swedish Cancer Society. BRCA-gene mutations and breast cancer in South African women (BMBSA) was supported by grants from the Cancer Association South Africa (Cansa) to EwR. UCHICAGO is supported by NCI Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA125183), R01 CA142996, U01CA161032 and by the Ralph and Marion Falk Medical Research Trust, the Entertainment Industry Fund National Women’s Cancer Research Alliance and the Breast Cancer research Foundation. OIO is an ACS Clinical Research Professor. UPENN study is supported by Basser Research Center (SMD, KN, TRR), Breast Cancer Research Foundation (KN), Komen Foundation for the Cure (SMD). The Women’s Cancer Program (WCP) at the Samuel Oschin Comprehensive Cancer Institute is funded by the American Cancer Society Early Detection Professorship (SDP-06-256-01-COUN). BFRC study: This work was supported by grant U101 CA164920 from the National Cancer Institute. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the Breast Cancer Family Registry (BCFR), nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government or the BCFR. BFBOCC is supported by: Lithuania (BFBOCC-LT): Research Council of Lithuania grant LIG-07/2012 and Hereditary Cancer Association (Pavelinio įvairio asėjimų);
introduction

Carrying an inherited mutation in the BRCA1 or BRCA2 gene increases a woman’s lifetime risk of developing breast, ovarian and other cancers. The estimated cumulative risk of developing breast cancer by the age of 70 in BRCA1 and BRCA2 mutation carriers varies between 43% to 88%; similarly, between 11% to 59% of mutation carriers will develop ovarian cancer by the age of 70 [1–3]. These considerable differences in disease manifestation suggest the existence of other genetic or environmental factors that modify the risk of cancer development. The Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIBM) was established in 2006 [4] and with more than 40,000 mutation carriers currently provides the largest sample size for reliable evaluation of even modest associations between single-nucleotide polymorphisms (SNPs) and cancer risk. CIBM studies have so far demonstrated that more than 25 SNPs are associated with the risk of developing breast or ovarian cancer for BRCA1 or BRCA2 carriers. These were identified through genome-wide association studies (GWAS) of breast or ovarian cancer in the general population or through BRCA1- and BRCA2-specific GWAS [5–8]. Cells harboring mutations in BRCA1 or BRCA2 show impaired homologous recombination (HR) [9–11] and are thus critically dependent on other members of the DNA repair machinery such as poly ADP ribose polymerase (PARP1) involved in the Base Excision Repair (BER) pathway. The BER pathway is crucial for the replacement of aberrant bases generated by different causes [12]. A deficiency in BER can give rise to a further accumulation of double-strand DNA breaks which, in the presence of a defective BRCA1 or BRCA2 background, could persist and lead to cell cycle arrest or cell death; this makes BRCA-deficient cells extremely sensitive to PARP inhibitors, as previously demonstrated [13]. We hypothesize that SNPs in PARP1 and other members of BER may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. SNPs in XRCC1, one of the main components of BER, have been recently evaluated within the CIMBA consortium [14], however a comprehensive study has not yet been performed of either XRCC1 or the other genes participating in BER.

In the present study, we used a tagging SNP approach to evaluate whether the common genetic variation in the genes involved in the BER pathway could be associated with cancer risk in a large series of BRCA1/2 mutation carriers using a two-stage approach. The first stage involved an analysis of 144 tag SNPs in 21,437 BRCA1/2 mutation carriers using a two-stage approach. In the second stage, the 36 SNPs showing the strongest evidence of association in stage I, were evaluated in a further 23,403 CIMBA mutation carriers included in the Collaborative Oncological Gene-environment Study (COGS) and genotyped using the iCOGS custom genotyping array.

Results

Breast cancer association

In stage I, 144 selected Tag SNPs covering the 18 selected BER genes were genotyped in 968 BRCA1 and 819 BRCA2 mutation carriers from five CIMBA centres (Spanish National Cancer ResearchCentre (CNIO), Hospital Clinico San Carlos (HCSC), Catalan Institute of Oncology (ICO), Demokritos and Milan Breast Cancer Study Group (MBCSG). Of those, 50 were excluded because of low call-rates, minor allele frequency (MAF)<0.05, evidence of deviation from Hardy Weinberg Equilibrium (p-value<10<−5) or monomorphism. Associations with
Author Summary

Women harboring a germ-line mutation in the BRCA1 or BRCA2 genes have a high lifetime risk to develop breast and/or ovarian cancer. However, not all carriers develop cancer and high variability exists regarding age of onset of the disease and type of tumor. One of the causes of this variability lies in other genetic factors that modulate the phenotype, the so-called modifier genes. Identification of these genes might have important implications for risk assessment and decision making regarding prevention of the disease. Given that BRCA1 and BRCA2 participate in the repair of DNA double strand breaks, here we have investigated whether variations, Single Nucleotide Polymorphisms (SNPs), in genes participating in other DNA repair pathway may be associated with cancer risk in BRCA carriers. We have selected the Base Excision Repair pathway because BRCA defective cells are extremely sensitive to the inhibition of one of its components, PARP1. Thanks to a large international collaborative effort, we have been able to identify at least two SNPs that are associated with increased cancer risk in BRCA1 and BRCA2 mutation carriers respectively. These findings could have implications not only for risk assessment, but also for treatment of BRCA1/2 mutation carriers with PARP inhibitors.

breast cancer risk were assessed for 94 SNPs, as summarized in Table S1. The 36 SNPs that showed evidence of association at p≤0.05 were selected for analysis in stage II. Of the 36 SNPs successfully genotyped in the whole CIMBA series comprising 15,252 BRCA1 and 8211 BRCA2 mutation carriers, consistent evidence of association with breast cancer risk (p-trend<0.05) was observed for six SNPs (Table 1). The strongest evidence of association was observed for rs1466785 in the NEIL2 gene (HR: 1.09, 95% CI (1.03–1.16), p=2.7×10^{-5}). Although three other SNPs were found to be associated with ovarian cancer risk in BRCA2 mutation carriers (p-trend<10^{-5}), these results were based on a relatively small number of ovarian cancer cases. Imputed data did not show any SNPs with substantially more significant associations with ovarian cancer risk except for rs3093926 in PARP2, associated with ovarian cancer risk in BRCA2 mutation carriers for which there was a SNP, rs61995542, with a stronger association (HR: 0.67, p=4.6×10^{-5}) (Figure S1).

Discussion

Based on the interaction of synthetic lethality that has been described between PARP1 and both BRCA1 and BRCA2, we hypothesize that this and other genes involved in the BER pathway could potentially be associated with cancer risk in BRCA1/2 mutation carriers. Several studies have recently investigated the association of some of the BER genes with breast cancer, however, no definitive conclusions can be drawn, given that some publications suggest that SNPs in these genes can be associated with breast cancer risk with marginal p-values while others rule out a major role of these genes in the disease [15–21]. There is only one study from the CIMBA consortium which has evaluated the role of three of the most studied SNPs in the XRCCI gene, c.-77C>T (rs3213245) p.Arg280His (rs25489) and p.Gln399Arg (rs25487), ruling out associations of these variants with cancer risk in BRCA1 and BRCA2 mutation carriers [14]. However, a comprehensive analysis of neither XRCCI nor the other genes involved in the pathway in the context of BRCA mutation carriers has been performed. In the present study we have assessed the common genetic variation of 18 genes participating in BER by using a two stage strategy.

Eleven SNPs showed evidence of association with breast and/or ovarian cancer at p<0.05 in stage II of the experiment (Table 1). Of those, six showed a p-trend value<0.01 and were therefore considered the best candidates for further evaluation. Only one of those six, rs1466785 in the NEIL2 gene (endonuclease VIII-like 2) showed an association with breast cancer risk while the other five, rs2304277 in OGG1 (β-guanine DNA glycosylase), rs167715 and rs4135087 in TDG (thymin-DNA glycosylase), rs3093926 in PARP2 (Poly(ADP-ribose) polymerase 2) and rs34259 in UNG (uracil-DNA glycosylase) were associated with ovarian cancer risk.

Ovarian cancer association

Due to lack of power we did not perform analysis of associations with ovarian cancer in stage I. However, we performed this analysis for the 36 SNPs tested in stage II. Although they had been selected based on their evidence of association with breast cancer risk, under the initial hypothesis they are also plausible modifiers of ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. We found four SNPs associated with ovarian cancer risk with a p-trend<0.01 in BRCA1 or BRCA2 mutation carriers (Table 1). The strongest association was found for rs2304277 in OGG1 in BRCA1 mutation carriers (HR: 1.12, 95% CI: 1.03–1.21, p=4.8×10^{-5}). The association was somewhat stronger under the dominant model (HR: 1.19, 95% CI: 1.08–1.3, p=6×10^{-5}). Although three other SNPs were found to be associated with ovarian cancer risk in BRCA2 mutation carriers (p-trend<10^{-3}), these results were based on a relatively small number of ovarian cancer cases. Imputed data did not show any SNPs with substantially more significant associations with ovarian cancer risk except for rs3093926 in PARP2, associated with ovarian cancer risk in BRCA2 mutation carriers for which there was a SNP, rs61995542, with a stronger association (HR: 0.67, p=4.6×10^{-5}) (Figure S1).
Table 1. Associations with breast and ovarian cancer risk for SNPs observed at p-trend < 0.05 in stage II of the experiment.

<table>
<thead>
<tr>
<th>BRCA1 carriers SNP name</th>
<th>Gene</th>
<th>Unaffected (Number)</th>
<th>Affected (Number)</th>
<th>Unaffected (MAF)</th>
<th>Affected (MAF)</th>
<th>HR per allelea</th>
<th>HR heterozygoteb</th>
<th>HR homozygoteb</th>
<th>p-trendc</th>
<th>p-hetc</th>
<th>p-homc</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast cancer rs3847954d</td>
<td>UNG</td>
<td>7455</td>
<td>7797</td>
<td>0.18</td>
<td>0.19</td>
<td>1.05 (1.00-1.11)</td>
<td>1.09 (1.02-1.16)</td>
<td>0.99 (0.84-1.16)</td>
<td>0.04</td>
<td>0.011</td>
<td>0.713</td>
</tr>
<tr>
<td>Ovarian cancer rs2072668</td>
<td>OGG1</td>
<td>12786</td>
<td>2461</td>
<td>0.22</td>
<td>0.23</td>
<td>1.09 (1.01-1.18)</td>
<td>1.16 (1.05-1.27)</td>
<td>1.03 (0.82-1.28)</td>
<td>0.016</td>
<td>3 × 10^-3</td>
<td>0.77</td>
</tr>
<tr>
<td>rs2269112</td>
<td>OGG1</td>
<td>12789</td>
<td>2461</td>
<td>0.17</td>
<td>0.18</td>
<td>1.11 (1.02-1.21)</td>
<td>1.11 (1.01-1.23)</td>
<td>1.21 (0.92-1.58)</td>
<td>0.013</td>
<td>0.014</td>
<td>0.268</td>
</tr>
<tr>
<td>rs2304277</td>
<td>OGG1</td>
<td>12783</td>
<td>2462</td>
<td>0.21</td>
<td>0.21</td>
<td>1.12 (1.03-1.21)</td>
<td>1.19 (1.08-1.33)</td>
<td>1.01 (0.79-1.30)</td>
<td>4.8 × 10^-3</td>
<td>6 × 10^-4</td>
<td>0.69</td>
</tr>
<tr>
<td>rs10161263</td>
<td>SMUG1</td>
<td>12790</td>
<td>2462</td>
<td>0.34</td>
<td>0.32</td>
<td>0.92 (0.86-0.99)</td>
<td>0.88 (0.80-0.97)</td>
<td>0.90 (0.78-1.04)</td>
<td>0.024</td>
<td>9 × 10^-3</td>
<td>0.49</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>BRCA2 carriers SNP name</th>
<th>Gene</th>
<th>Unaffected (Number)</th>
<th>Affected (Number)</th>
<th>Unaffected (MAF)</th>
<th>Affected (MAF)</th>
<th>HR per allele</th>
<th>HR heterozygote</th>
<th>HR homozygote</th>
<th>p-trend</th>
<th>p-het</th>
<th>p-hom</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast cancer rs2072668e</td>
<td>OGG1</td>
<td>3879</td>
<td>4328</td>
<td>0.23</td>
<td>0.21</td>
<td>0.91 (0.85-0.98)</td>
<td>0.95 (0.87-1.04)</td>
<td>0.75 (0.62-0.91)</td>
<td>0.018</td>
<td>0.098</td>
<td>7 × 10^-3</td>
</tr>
<tr>
<td>rs2269112f</td>
<td>OGG1</td>
<td>3880</td>
<td>4329</td>
<td>0.17</td>
<td>0.16</td>
<td>0.91 (0.84-0.99)</td>
<td>0.93 (0.85-1.03)</td>
<td>0.76 (0.58-0.99)</td>
<td>0.035</td>
<td>0.083</td>
<td>0.054</td>
</tr>
<tr>
<td>rs3136811g</td>
<td>POLB</td>
<td>3873</td>
<td>4321</td>
<td>0.06</td>
<td>0.07</td>
<td>1.12 (1.05-1.25)</td>
<td>1.17 (1.03-1.32)</td>
<td>0.86 (0.49-1.48)</td>
<td>0.032</td>
<td>0.019</td>
<td>0.715</td>
</tr>
<tr>
<td>rs2304277h</td>
<td>OGG1</td>
<td>3880</td>
<td>4330</td>
<td>0.21</td>
<td>0.19</td>
<td>0.91 (0.84-0.97)</td>
<td>0.94 (0.85-1.03)</td>
<td>0.74 (0.60-0.91)</td>
<td>0.013</td>
<td>0.058</td>
<td>0.01</td>
</tr>
<tr>
<td>rs1466785i</td>
<td>NEIL2</td>
<td>3879</td>
<td>4330</td>
<td>0.4</td>
<td>0.43</td>
<td>1.09 (1.03-1.16)</td>
<td>1.20 (1.09-1.37)</td>
<td>1.16 (1.03-1.31)</td>
<td>2.7 × 10^-3</td>
<td>1 × 10^-4</td>
<td>0.455</td>
</tr>
<tr>
<td>Ovarian cancer rs167715</td>
<td>TGD</td>
<td>7577</td>
<td>631</td>
<td>0.12</td>
<td>0.09</td>
<td>0.76 (0.62-0.94)</td>
<td>0.72 (0.58-0.90)</td>
<td>0.89 (0.41-1.89)</td>
<td>7.4 × 10^-3</td>
<td>4.1 × 10^-3</td>
<td>0.866</td>
</tr>
<tr>
<td>rs3093926j</td>
<td>PARP2</td>
<td>7580</td>
<td>631</td>
<td>0.07</td>
<td>0.05</td>
<td>0.64 (0.49-0.84)</td>
<td>0.67 (0.49-0.89)</td>
<td>0.75 (0.62-0.91)</td>
<td>0.018</td>
<td>0.098</td>
<td>7 × 10^-3</td>
</tr>
<tr>
<td>rs4135087i</td>
<td>TGD</td>
<td>7580</td>
<td>631</td>
<td>0.09</td>
<td>0.11</td>
<td>1.32 (1.09-1.59)</td>
<td>1.33 (1.07-1.65)</td>
<td>1.67 (0.84-3.28)</td>
<td>2.8 × 10^-3</td>
<td>3.8 × 10^-3</td>
<td>0.185</td>
</tr>
<tr>
<td>rs34259</td>
<td>UNG</td>
<td>7580</td>
<td>631</td>
<td>0.2</td>
<td>0.17</td>
<td>0.80 (0.69-0.94)</td>
<td>0.84 (0.70-1.01)</td>
<td>0.51 (0.29-0.90)</td>
<td>7.6 × 10^-3</td>
<td>0.025</td>
<td>0.028</td>
</tr>
</tbody>
</table>

*aHazard Ratio per allele (1 df) estimated from the retrospective likelihood analysis.
bHazard Ratio under the genotype specific models (2df) estimated from the retrospective likelihood analysis.
cp-values were based on the score test.
dHR per allele of 1.69 and p-trend of 1 × 10^-4 for BRCA2 mutation carriers in stage I of the study.

eHR per allele of 1.43 and p-trend of 0.01 for BRCA1 mutation carriers in stage I of the study.
fHR per allele of 1.30 and p-trend of 0.03 for BRCA2 mutation carriers in stage I of the study.
gHR per allele of 0.64 and p-trend of 0.057 for BRCA2 mutation carriers in stage I of the study.
hHR per allele of 1.25 and p-trend of 0.04 for BRCA1 mutation carriers in stage I of the study.
iHR per allele of 1.25 and p-trend of 0.058 for BRCA2 mutation carriers in stage I of the study.
jrs3093926 did not yield results under the genotype specific model due to the low minor allele frequency.
kHighlighted in bold are those SNPs showing strongest associations with breast or ovarian cancer risk (p < 0.01).

Complete description of results from stage I are included in Supplementary Table S1.

doi:10.1371/journal.pgen.1004256.t001

Base Excision Repair Genes Are BRCA1/2 Modifiers

PLOS Genetics | www.plosgenetics.org 6 April 2014 | Volume 10 | Issue 4 | e1004256
been proven to alter the transcriptional response to oxidative stress [24]. Moreover, this SNP has been proposed to partly explain the inter-individual variability observed in NEIL2 expression levels in the general population and has been proposed as a potential risk modifier of disease susceptibility [25].

Several studies have been published showing associations between SNPs in NEIL2 and lung or oropharyngeal cancer risk [26,27] but to our knowledge, no association with breast cancer risk has been reported. We hypothesize that the potential association observed in the present study could be explained by the interaction between NEIL2 and BRCA2, each of them causing a deficiency in the BER and HR DNA repair pathways, respectively. This would explain why the breast cancer risk modification due to rs1466785 would only be detected in the context of BRCA2 mutation carriers and not in the general population.

The strongest evidence of association found in BRCA1 carriers was between rs2304277 in the OGG1 gene and ovarian cancer risk. The association was more significant when considering the dominant model. OGG1 removes 8-oxodeoxyguanosine which is generated by oxidative stress and is highly mutagenic, and it has been suggested that SNPs in the gene could be associated with cancer risk [28–31]. This is an interesting result, given that to date only one SNP, rs4691139 in the 4q35.3 region, also identified through the iCOGS effort, has been found to modify ovarian cancer risk specifically in BRCA1 carriers [32]. SNP rs2304277 is located in the 3'UTR (untranslated region) of the gene and is probably not the causal variant, however, in this case imputations through the 1000 Genome did not show better results for a more plausible causal SNP.

We have identified four SNPs associated with ovarian cancer risk in BRCA2 mutation carriers, rs167715 and rs4135087 in the TDG gene, rs34259 in the UNG gene and rs3093926 in PARP2. However, these last results should be interpreted with caution given that the number of BRCA2 carriers affected with ovarian cancer is four-fold lower than for BRCA1 carriers and the statistical power was therefore more limited, increasing the possibility of false-positives. In the case of PARP2, imputed data showed a lower p-value of association (4 × 10^−6) for another SNP, rs61995542, that had a slightly higher MAF than rs3093926 (0.074 vs. 0.067) (Figure S1). However, it must still be interpreted with caution due to small number of ovarian cancer cases in the BRCA2 group.

It is worth noting that, four of the five genes for which strongest evidence of association was observed, are all DNA glycosylases participating in the initiation of BER by removing damaged or mismatched bases. Apart from the already mentioned NEIL2 and OGG1, TDG initiates repair of G/T and G/U mismatches commonly associated with CpG islands, while UNG removes uracil in DNA resulting from deamination of cytosine or replicative incorporation of dUMP. We have not found strong associations with SNPs in genes involved in any other parts of the pathway, such as strand incision, trimming of ends, gap filling or ligation. It has been suggested that at least in the case of uracil repair, base removal is the major rate-limiting step of BER [33]. This is consistent with our findings, suggesting that SNPs causing impairment in the function of these specific DNA glycosylases

![Figure 1. p-values of association (−log10 scale) with breast cancer risk in BRCA2 carriers for genotyped and imputed SNPs in the NEIL2 gene. SNP rs1466785 is indicated with a purple arrow and the best causal imputed SNPs, rs804276 and rs804271 are indicated with a red arrow. Colors represent the pairwise r^2. Plot generated with LocusZoom (42) (http://csg.sph.umich.edu/locuszoom/). doi:10.1371/journal.pgen.1004256.g001](http://csg.sph.umich.edu/locuszoom/)
could give rise to accumulation of single strand breaks and subsequently DNA double strand breaks that, in the HR defective context of BRCA1/2 mutation carriers would increase breast and ovarian cancer risk.

The fact that the SNPs tested are located in genes participating in the same DNA repair pathway as PARPi, make them especially interesting, not only as risk modifiers but also because they could have an impact on patients’ response to treatment with PARPi inhibitors. BRCA1/2 mutation carriers harboring a potential modifier SNP in DNA glycosylases could be even more sensitive to PARPi due to a constitutional slight impairment of the BER activity. This is a hypothesis that should be confirmed in further studies. The design of this study in two stages, the hypothesis-based approach adopted to select genes, and that it is based on the largest possible series of BRCA1 and BRCA2 carriers available nowadays, mean that the results obtained are quite solid. However, the study still has some limitations such as the possible existence of residual confounding due to environmental risk factors for which we did not have information.

In summary, we have identified at least two SNPs, rs1466785 and rs2304277, in the DNA glycosylases NEIL2 and OGG1, potentially associated with increased breast and ovarian cancer risks in BRCA2 and BRCA1 mutation carriers, respectively. Our results suggest that glycosylases involved in the first steps of the BER pathway may be cancer risk modifiers in BRCA1/2 mutation carriers and should be more comprehensively studied. If confirmed, these findings could have implications not only for risk assessment, but also for treatment of BRCA1/2 mutation carriers with PARPi inhibitors.

Materials and Methods

Subjects

Eligible subjects were female carriers of deleterious mutations in BRCA1 or BRCA2 aged 18 years or older [6]. A total of 55 collaborating CIMBA studies contributed genotypes for the study. Numbers of samples included from each are provided in Table S2. A total of 1,787 mutation carriers (968 with mutations in BRCA1 and 819 with mutations in BRCA2) from the CNIO, HCSC, ICO, Demokritos and MBCSG were genotyped in the first stage of the study. Stage II included 23,463 CIMBA samples (15,252 with mutations in BRCA1 and 8,211 with mutations in BRCA2). All carriers participated in clinical and/or research studies at the host institution under IRB-approved protocols.

Methods stage I

Selection and genotyping of SNPs. Eighteen genes (UNG, SMUG1, MBD4, TDG, OGG1, MUTYH, NTHLI1, MPG, NEIL1, NEIL2, APEX1, APEX2, LIG3, XRCC1, PNKP, POLB, PARP1 and PARP2) involved in the BER pathway were selected, based on the information available at http://www.cgal.icnet.uk/DNA_Repair_Genes.html as at the 31st December, 2009. Tag SNPs for the selected genes were defined using Haplovizview 4.0 (http://www.broad.mit.edu/mpg/haplovizview) with an r^2 threshold of 0.8 and a minimum minor allele frequency of 0.05. In addition, SNPs with potentially functional effects already described in the literature were selected. A final number of 144 SNPs was included in an oligonucleotide pool assay for genotyping using the Illumina Veracode technology (Illumina Inc., San Diego, CA). Three hundred nanograms of DNA from each sample were genotyped using the GoldenGate Genotyping Assay with Veracode technology according to the published Illumina protocol. Genotype clustering and calling were carried out using the GenomeStudio software. SNPs with a call rate <0.95 were excluded from further analysis. Duplicate samples and CEPH trios (Coriell Cell Repository, Camden, NJ) were genotyped across the plates. SNPs showing Mendelian allele-transmission errors or showing discordant genotypes across duplicates were excluded.

Statistical analysis. To test for departure from Hardy-Weinberg equilibrium (HWE), a single individual was randomly selected from each family and Pearson’s X^2 Test (1 df) was applied to genotypes from this set of individuals. The association of the SNPs with breast cancer risk was assessed by estimating hazard ratios (HR) and their corresponding 95% confidence intervals (CI) using weighted multivariable Cox proportional hazards regression with robust estimates of variance [34]. For each mutation carrier, we modeled the time to diagnosis of breast cancer from birth, censoring at the first of the following events: bilateral prophylactic mastectomy, breast cancer diagnosis, ovarian cancer diagnosis, death or date last known to be alive. Subjects were considered affected if their age at censoring corresponded to their age at diagnosis of breast cancer and unaffected otherwise. Weights were assigned separately for carriers of mutations in BRCA1 and BRCA2, by age and affection status, so that the weighted observed incidences in the sample agreed with established estimates for mutation carriers [1]; [34].

We considered log-additive and co-dominant genetic models and tested for departure from HR = 1 by applying a Wald test based on the log-HR estimate and its standard error. Additional independent variables included in all analyses were year of study, centre and country. All statistical analyses were carried out using Stata: Release 10 (StataCorp, 2007. Stata Statistical Software: Release 10.0. College Station, TX: Stata Corporation LP). Robust estimates of variance were calculated using the cluster subcommand, applied to an identifier variable unique to each family.

Methods stage II

iCOGS SNP array. Stage II of the experiment was performed as part of the iCOGS genotyping experiment. The iCOGS custom array was designed in collaboration between the Breast Cancer Association Consortium (BCAC), the Ovarian Cancer Association Consortium (OCAC), the Prostate Cancer Association Group to Investigate Cancer Associated in the Genome (PRACTICAL) and CIMBA. The final design comprised 211,155 successfully manufactured SNPs of which approximately 17.5% had been proposed by CIMBA. A total of 43 SNPs were nominated for inclusion on iCOGS based on statistical evidence of association in stage I of the present study (p<0.05). Of these, 36 were successfully manufactured and genotyped in CIMBA mutation carriers.

iCOGS genotyping and quality control. Genotyping was performed at Mayo Clinic and the McGill University and Génôme Québec Innovation Centre (Montreal, Canada). Genotypes were called using Illumina’s GenCall algorithm. Sample and quality control process have been described in detail elsewhere [32,35]. After the quality control process a total of 23,463 carriers were genotyped for the 36 selected SNPs.

Statistical analysis. Both breast and ovarian cancer associations were evaluated in stage II. Censoring for breast cancer followed the same approach as in stage I. Censoring for ovarian cancer risk occurred at risk-reducing salpingo-oophorectomy or last follow-up.

The genotype-disease associations were evaluated within a survival analysis framework, by modelling the retrospective likelihood of the observed genotypes conditional on the disease phenotypes [9,34,36,37]. The associations between genotype and breast or ovarian cancer risk were assessed using the 1 d.f. score test statistic based on this retrospective likelihood. To allow for the
non-independence among related individuals, we accounted for the correlation between the genotypes by estimating the kinship coefficient for each pair of individuals using the available genomic data [34,35,36]. These analyses were performed in R using the GenABEL libraries and custom-written functions in FORTRAN and Python.

To estimate the magnitude of the associations (HRs), the effect of each SNP was modeled either as a per-allele HR (multiplicative model) or as genotype-specific HRs, and was estimated on the log-scale by maximizing the retrospective likelihood. The retrospective likelihood was fitted using the pedigree-analysis software MENDEL. The variances of the parameter estimates were obtained by robust variance estimation based on reported family membership. All analyses were stratified by country of residence and based on calendar-year and cohort-specific breast cancer incidence rates for mutation carriers. Countries with small number of mutation carriers were combined with neighbouring countries to ensure sufficiently large numbers within each stratum. USA and Canada were further stratified by reported Ashkenazi Jewish (AJ) ancestry.

**Imputation.** Genotypes were imputed separately for *BRCA1* and *BRCA2* mutation carriers using the v3 April 2012 release (Genomes Project et al., 2012) as reference panel. To improve computation efficiency we used a two-step procedure which involved pre-phasing in the first step and imputation of the phased data in the second. Pre-phasing was carried out using the SHAPEIT software [40]. The IMPUTE version 2 software was used for the subsequent imputation [41]. SNPs were excluded from the association analysis if their imputation accuracy was r2<0.3 or MAF<0.005 in any of the data sets. For the final analysis we only took in account those SNPs with an imputation accuracy r2>0.7, MAF>0.01 and being located in the region comprised within 15 kilo bases (kb) downstream and upstream the gene where the genotyped SNP showing an association was located (Table 1). Associations between imputed genotypes and breast cancer risk were evaluated using a version of the score test as described above but with the posterior genotype probabilities replacing the genotypes.

**Supporting Information**

**Figure S1** p-values of association (~log10 scale) with breast and ovarian cancer risk in *BRCA1* and *BRCA2* carriers for genotyped and imputed SNPs considering 15 kb upstream and downstream the genes in which SNPs described in Table 1 were located. rs numbers of SNPs from Table 1 are indicated at the top of each panel and in the graph with a purple arrow. For *PARP2* gene, the imputed SNP with the strongest association, rs61995542 is indicated with a red arrow. Colors represent the pairwise r2. (PPT)

**Table S1** Association with breast cancer for the 94 SNPs selected for analysis in stage I. (XLS)

**Table S2** number of *BRCA1* and *BRCA2* carriers by study. (XLS)

**Acknowledgments**

CNIO acknowledgments: Genotyping was provided by ‘Centro Nacional de Geronotizado - Instituto de Salud Carlos III’ (CeGen-ISCH; www.cegen.org). COGS acknowledgments: this study would not have been possible without the contributions of the following: Per Hall (COGS); Douglas F. Easton (BCAC), Andrew Berchuck (OCAC), Rosalind A. Ezles, Douglas F. Easton, Ali Amin Al Olama, Zsofia Kote-Jarai (PRACTICAL), Georgia Chenevix-Trench, Antonis Antoniou, Fergus Couch and Ken Offit (CIMBA); Joe Dennis, Alison M. Dunning, Andrew Lee, and Ed Dicks (Cambridge); Javier Benitez, Anna Gonzalez-Neira and the staff of the CNIO genotyping unit, Jacques Simard and Daniel C. Tessler, Francois Bacot, Daniel Vincent, Sylvie LaBoisserie and Frederic Robidoux and the staff of the McGill University and Genome Quebec Innovation Centre, Stig E. Bojesen, Sune F. Nielsen, Borge G. Nordestgaard, and the staff of the Copenhagen DNA laboratory, and Julie M. Cunningham, Sharon A. Windebank, Christopher A. Hilkier, Jelfriet Meyer and the staff of Mayo Clinic Genotyping Core Facility.

Swedish Breast Cancer Study (SWE-BRCA): SWE-BRCA members are Ake Borg, Department of Oncology, Lund University, Lund. Anna Olverholm, Department of Clinical Genetics, Sahlgrenska University Hospital, Gothenburg, Sweden. Anna von Wachenfeldt, Department of Oncology, Karolinska University Hospital, Stockholm, Sweden. Annelie Liljegren, Department of Oncology, Karolinska University Hospital, Stockholm, Sweden. Anna Lindblom, Department of Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden. Beatrice Melin, Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden. Brita Arver, Department of Oncology, Karolinska University Hospital, Stockholm, Sweden. Christina Edwindsdotter Ardnor, Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden. Gisela Barbany Bustina, Department of Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden. Häkan Olsson, Department of Oncology, Lund University Hospital, Lund, Sweden. Hans Ehrencreuna, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Department of Clinical Genetics, Lund University Hospital, Lund, Sweden. Helena Jernström, Department of Oncology, Lund University, Lund, Sweden. Johanna Rantala, Department of Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden. Karin Henriksson, Oncologic Centre, Regional Tumour Registry, Lund University Hospital, Lund, Sweden. Katja Harbst, Department of Oncology, Lund University, Lund, Sweden. Margareta Nordling, Department of Clinical Genetics, Sahlgrenska University Hospital, Gothenburg, Sweden. Maria Soller, Department of Clinical Genetics, Lund University Hospital, Lund, Sweden. Marie Stemmark-Axosmwa, Department of Clinical Genetics, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden. Maritta Hellström Pigg, Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala. Monica Emanuelsen, Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden. Niklas Loman, Department of Oncology, Lund University Hospital, Lund, Sweden. Per Karlsson, Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden. Richard Rosenquist, Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden. Sigrun Liedgren, Division of Clinical Genetics, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden. SWE-BRCA, Ulf Kristofferson, Department of Clinical Genetics, Lund University Hospital, Lund, Sweden. Zakaria Einheig, Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden.

The University of Chicago Center for Clinical Cancer Genetics and Global Health (UCHICAGO) wish to thank Cecilia Zvoce, Qiu Niu, physicians, genetic counselors, research nurses and staff of the Cancer Risk Clinic for their contributions to this resource, and the many families who contribute to our program.

UCSF Cancer Risk Program and Helen Diller Family Comprehensive Cancer Center; We would like to thank Ms. Salina Chan for her data management and the following genetic counselors for participant recruitment: Beth Crawford, Nicola Stewart, Julie Mak, and Kate Launvik.

Baltic Familial Breast Ovarian Cancer Consortium (BFBOCC) study: we acknowledge Vilius Rudaitis, Laimonas Griskievicius, BFBOCC-LV acknowledge Drs. Janis Eglitis, Anna Krilova and Aivars Stengrevics. BRCA-gene mutations and breast cancer in South African women (BMBSA) wish to thank the families who contribute to the BMBSA study.

Beckman Research Institute of the City of Hope (BRICOH) study: we wish to thank Greg Wilhoite, Linda Steele, and Marie Pinto for their work in participant enrollment and biospecimen and data management.

The City of Hope Clinical Genetics Community Research Network: we wish to thank the collaborating clinicians in the Clinical Cancer Genetics Community Research Network for patient recruitment and follow up; Kai Yang for masterful assistance with the database, and Hazel Marivelles for network coordination.
Base Excision Repair Genes Are BRCA1/2 Modifiers
Family Cancer Clinics, and the Clinical Follow Up Study for their contributions to this resource, and the many families who contribute to kConFab.

National Israeli Cancer Control Center (NICCC): we wish to thank the NICCC National Familial Cancer Consultation Service team led by Sara Dishon, the lab team led by Dr. Flavio Lejkovich, and the research and operations team led by Dr. Mila Pinchev.

The Ohio State University Comprehensive Cancer Center (OSUCCG) acknowledges Leigha Senter, Kevin Sweet, Caroline Caven and Michelle O’Connor were instrumental in accrual of study participants, ascertainment of medical records and database management. Samples were processed by the OSU Human Genetics Sample Bank.SMCC team wishes to acknowledge the assistance of the Meirav Comprehensive breast cancer center team at the Sheba Medical Center for assistance in this study.

Sheba Medical Center (SMC): SMC team wishes to acknowledge the assistance of the Meirav Comprehensive breast cancer center team at the Sheba Medical Center for

---

**References**


---

**Author Contributions**

Conceived and designed the experiments: AO RLM Kku ACA. Contributed reagents/materials/analysis tools: AO RLM Kku GTF VA PFP IBH MD OD TR-c IC KMB RAC PS LM DB AL BR JN NL0 HE OHO SMBM KND TRR BKA BKC CW JLe EMJ ASW MBD MS JHo MBT SSB RJ CDM EJ-R LSi SLN YCD Tp-OH JLe BE AMG MI HT LTM JNW H-Kwe SMa Bn Bz SSB FF MSV AVV LP LO MGT PR DY JGa SD FR RF GE FLa RE JI ARD TD GJc HcSh CB MTO FDo MPS LiW LWM AD JK CF AKG KKS BBW KR CE AM ND NA HDJ PN DS SW DSP 65K Kva Rvm AG AsL OMS SmaZ Fda Fps KG MF KT FB GW KB Tkr TcA KcA HcA MAR TAM-O Lus JcEl JcEl Eih JcEl ABBG Nh JMC GmHd RBBdL PD EO CL AT MMJ AC JcC JcJ KdJ KJh OtJ CM MmST Mtr Mth ShO LiS CsJv Mr Nk Kz Rrm Afr Cfs CrG Dkg GpK Mtk Abc Cmp MhG PmL FlA AAm GmM Abt ABo IsP LmTh Tak UbJ Eff YL SpS Js DFe KF JcG GtC AcA Jb. The paper was revised: AO RLM Kku ACA Jb.

PLOS Genetics | www.plosgenetics.org 11 April 2014 | Volume 10 | Article 4 | e1004256